J Pharmacol Exp Ther 2021 Jul 1. Epub 2021 Jul 1.
AbbVie Inc., United States.
Brimonidine, a selective alpha-adrenoceptor agonist, displays putative retinal cyto-neuroprotective activity and An intravitreal sustained-release brimonidine implant, Brimonidine Posterior Segment Drug Delivery System (brimonidine DDS), allowing targeted drug delivery to the retina, has been developed for potential clinical application. This study evaluates the posterior segment pharmacokinetics of brimonidine DDS implant in the monkey eye, and applies translational pharmacokinetic modeling to predict tissue exposure in the human eye. Anesthetized Cynomolgus monkeys received a single intravitreal injection of brimonidine DDS 400 µg implant before removal of study eyes at Days 7, 30, 60, 92, 120, and 150 post-implant (3-4 animals per time point) for assay of brimonidine in aqueous humor, vitreous, and retina samples. Read More